Exagen engages in the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling differential diagnosis and improving therapeutic intervention. Co. commercializes a portfolio of testing products under its AVISE® brand, several of which incorporate Cell-Bound Complement Activation Products (CB-CAPs) technology. CB-CAPs assess the activation of the complement system, a biological pathway that is implicated across various autoimmune and autoimmune-related diseases. Co.'s testing product, AVISE® CTD, enables differential diagnosis for patients presenting with symptoms indicative of connective tissue diseases and other diseases with overlapping symptoms. The XGN average annual return since 2019 is shown above.
The Average Annual Return on the XGN average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether XGN average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the XGN average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|